Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Primo studio sull'incremento della dose nell'uomo che valuta la sicurezza del dispositivo TheraSphere Prostate Cancer (PCa). (VOYAGER)

29 ottobre 2026 aggiornato da: Boston Scientific Corporation

Uno studio di fattibilità iniziale per valutare la sicurezza del dispositivo TheraSphere Prostate Cancer (PCa) in pazienti con cancro alla prostata clinicamente localizzato

The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

TheraSphere™ Y-90 Glass Microspheres are a targeted cancer therapy consisting of tiny glass beads containing radioactive Yttrium-90 (Y-90), which are injected directly into the blood vessel feeding the tumor through a microcatheter using advanced imaging guidance. The glass microspheres enter the tumor's blood supply, lodge within the blood vessels feeding the tumor, and release radiation to the tumor. The radiation works to destroy the tumor cells from within, thus limiting radiation exposure to surrounding normal tissues, a process referred to as selective internal radiation therapy (SIRT).

This study aims to investigate the maximum safe radiation dose of TheraSphere Prostate Cancer (PCa) device that can be delivered in patients with clinically localized prostate cancer. The study will also evaluate the full safety profile, technical feasibility, efficacy, and quality of life metrics of the TheraSphere PCa device.

Participants will be asked to complete the following:

  • At least two image-guided visits, including a mapping assessment (without Technetium Tc albumin aggregated [Tc-MAA]) prior to treatment
  • One treatment visit, including image-guided assessments
  • Fifteen post-treatment follow-up visits for a total of approximately 20 visits over the 5-year study period

Note: the VOYAGER Study is a staged investigational device exemption (IDE) study; therefore, the full enrollment of 21 to 36 subjects is subject to FDA approval following safety review of the first 10 subjects enrolled.

Tipo di studio

Interventistico

Iscrizione (Stimato)

36

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Northwestern Memorial Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

50 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  1. Subject has ability to comprehend and willingness to sign and date the IRB-approved study informed consent form (ICF), and to comply with the study testing, procedures, and follow-up schedule.

  2. Histologic confirmation of adenocarcinoma of the prostate by MR-fusion biopsy. Referral biopsy for eligibility must be completed between 180 days and 6 weeks prior to mapping procedure.

  3. Subject with favorable intermediate risk clinically localized prostate cancer defined per NCCN Guidelines version 3.2022 as follows:

    • Favorable intermediate-risk has all the following:

    • i. One Intermediate Risk Factor (IRF):

      1. cT2b-cT2c
      2. Grade Group 2 or 3
      3. PSA 10-20 ng/mL
    • ii. Grade Group 1 or 2

    • iii. <50% biopsy cores positive (e.g., <6 of 12 cores)

  4. Staging MRI must confirm American Joint Committee on Cancer (AJCC, 8th edition) stage T1, T2a, T2b or T2c.

  5. Whole prostate gland volume ≥ 60 cc (measured on MRI)

  6. International Prostate Score Symptom (I-PSS) ≤ 18

  7. Estimated life expectancy of >5 years according to NCCN guideline's tools (NCCN v03.2022) who has declined or is ineligible for Standard of Care treatments (observation, active surveillance, surgery, and radiation therapies [brachytherapy/external beam radiation therapy])

  8. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

  9. Angiographic inclusion criteria:

    • a. Type I to IV prostate artery origins on both hemiglands.1
    • b. No evidence of procedure limiting vascular abnormalities (aneurysms, stenosis, shunt, fistula, occlusion) or morphologic asymmetric single prostate artery on either side (hemigland)
    • c. Bilaterally accessible solitary prostatic arteries.
    • d. Complete perfusion of the prostate gland via a single dominant vessel for each hemigland
  10. Have adequate organ and bone marrow function within 30 days prior to index procedure, as defined below:

    • a. International Normalized Ratio (INR) ≤ 1.2 (in absence of anticoagulation)
    • b. Platelets ≥ 75,000/L
    • c. GFR ≥ 40 mL/min/1.73m2
    • d. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • e. Hemoglobin (Hgb) ≥ 9.0 g/dL (Note: the use of transfusion or other intervention to achieve adequate bone marrow function is acceptable
    • f. ALT/AST ≤ 5 x upper limit of normal (ULN)
    • g. Bilirubin ≤ 2 mg/dL
  11. Patients with known Human Immunodeficiency Virus (HIV) infection are eligible with well controlled HIV infection, no current or previous AIDS-related complications and CD4+ T-cell (CD4+) counts ≥ 350 cells/uL

Exclusion Criteria:

  1. Direct evidence of regional or distant metastases after appropriate staging studies per NCCN guidelines (v03.2022)

  2. Histological evidence of intraductal features

  3. Previous treatments (pelvic radiotherapy, surgery, prostate artery embolization [PAE], transurethral resection of the prostate [TURP] or previous/ planned hormonal therapy

  4. History of Crohn's Disease, ulcerative colitis, or ataxia telangiectasia, current gross haematuria, or current urinary catheter

  5. Subjects with ongoing urinary tract infection, prostate abscess, prostatitis, or neurogenic bladder

  6. Prior significant rectal surgery (haemorrhoidectomy is acceptable)

  7. Prior invasive malignancy unless disease free for a minimum of 3 years. Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease

  8. Hip prosthesis

  9. Medical contraindication to undergo contrast-enhanced angiography, CT scan and magnetic resonance imaging (MRI), or arterial catheterization, or known history of hypersensitivity reactions to iodinated and gadolinium-based contrast product

  10. Angiographic exclusion criteria:

    • a. Perfusion to tissues outside the Planning Target Volume (PTV) that cannot be corrected by placement of the catheter distal to collateral vessels or the application of standard angiographic techniques, such as coil embolization
    • b. Type V prostatic artery origin on either side

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: TheraSphere PCa Dose Escalation

Participants will be treated in cohorts of three across three sequential dose levels:

  • Dose Level 1 (or starting dose) = 175 Gy; however, a provisional lower dose level, Dose Level -1 = 150 Gy, may be utilized in case de-escalation is warranted at Dose Level 1.
  • Dose Level 2 = 200 Gy
  • Dose Level 3 = 225 Gy

Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).

Altri nomi:
  • TheraSphere PCa - Microsfere di vetro con ittrio-90

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maximum tolerated radiation dose of TheraSphere PCa
Lasso di tempo: Through 90 days post-treatment

• The Maximum Tolerated Dose (MTD) of Yttrium-90 Glass Microspheres (TheraSphere™ PCa) is based on rate of dose limiting toxicity (DLT) through 90 days, defined as any ≥ grade 3 adverse event (AE) according to CTCAE v.5

Through 90 days post-treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of adverse events (AEs)
Lasso di tempo: Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)

The following AEs/SAEs will be assessed in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0:

  • Rate of any ≥ grade 3 AEs
  • Rate of AEs of interest, i.e., any ≥ Grade 2 GI/GU and erectile dysfunction toxicities
  • Rate of any treatment-emergent AEs and treatment-emergent SAEs
  • Rate of any treatment-related AEs and treatment-related SAEs
  • AEs related to non-target TheraSphere PCa distribution
Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)
Rate of success of delivering intended dose
Lasso di tempo: Immediately post-treatment

• The ability to deliver the intended TheraSphere PCa absorbed dose (+/- 20%) to the treatment volume based on post-treatment PET derived absorbed dose.

Immediately post-treatment
Recurrence Free Survival
Lasso di tempo: Through 5 years post-treatment

• Biochemical Recurrence Free Survival (bRFS) based on PSA according to the Phoenix criteria (RTOG-ASTRO definition). Biochemical recurrence of prostate cancer after curative treatment is defined as a PSA rise of ≥ 2 ng/mL above the post-treatment nadir.

Through 5 years post-treatment
Progression free survival (PFS)
Lasso di tempo: Through 5 years post-treatment

• Progression free survival (PFS) and local progression free survival (LPFS), defined as time from inclusion until one of the following events, whichever comes first: biochemical progression (Phoenix criteria) or clinical progression.

Through 5 years post-treatment
Prostate cancer specific survival
Lasso di tempo: Through 5 years post-treatment

• Prostate cancer specific survival will be measured as the number of days between treatment with TheraSphere PCa and death by prostate cancer.

Through 5 years post-treatment
Overall survival (OS)
Lasso di tempo: Through 5 years post-treatment

• OS will be measured as the number of days between treatment with TheraSphere PCa and death by any cause.

Through 5 years post-treatment
Rate of subsequent prostate anticancer treatment
Lasso di tempo: Through 5 years post-treatment

• A summary table with number of subjects (%) who received subsequent definitive or systematic therapy and type of therapies received will be presented.

Through 5 years post-treatment
Rate of histopathological recurrence
Lasso di tempo: Through 5 years post-treatment

• Rate of recurrence based on histopathological assessment of prostate MR/US-fusion biopsy in patients with evidence of progression.

Through 5 years post-treatment
Quality of Life (QoL) measured by EPIC-26
Lasso di tempo: Through 5 years post-treatment

• Change from baseline measured through Expanded Prostate Cancer Index Composite (EPIC-26).

Through 5 years post-treatment
Quality of Life (QoL) measured by MSHQ
Lasso di tempo: Through 5 years post-treatment

• Change from baseline measured through Male Sexual Health Questionnaire (MSHQ).

Through 5 years post-treatment
Quality of Life (QoL) measured by I-PSS
Lasso di tempo: Through 5 years post-treatment

• Change from baseline measured through International Prostate Symptom Score (I-PSS).

Through 5 years post-treatment
Maximum urinary flow (Qmax)
Lasso di tempo: Through 5 years post-treatment

• Change from baseline

Through 5 years post-treatment
Post-void residual (PVR) urine test
Lasso di tempo: Through 5 years post-treatment

• Change from baseline

Through 5 years post-treatment
Dose Distribution
Lasso di tempo: Through one-week post-treatment

• Dose Volume Histogram (DVH) and evaluation of D90 from post-treatment Y90 PET-MRI/CT.

Through one-week post-treatment

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Prostatic imaging assessment
Lasso di tempo: Through 5 years post-treatment

• Qualitative analysis of multi-parametric MRI (mp-MRI) and PI-RADS score

Through 5 years post-treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Samdeep Mouli, M.D., M.S., Northwestern Medical Hospital
  • Investigatore principale: Mark Hurwitz, MD, Westchester Medical Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 aprile 2024

Completamento primario (Stimato)

1 gennaio 2028

Completamento dello studio (Stimato)

1 ottobre 2032

Date di iscrizione allo studio

Primo inviato

28 novembre 2023

Primo inviato che soddisfa i criteri di controllo qualità

21 dicembre 2023

Primo Inserito (Effettivo)

5 gennaio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • S2493

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .